Literature DB >> 6329117

Acyclovir. Pharmacology and clinical experience.

O L Laskin.   

Abstract

Acyclovir is a selective antiherpes agent. Its selective activity is by exploitation of differences between the herpes-specific and host cell enzymes. The major route of elimination of acyclovir is via the kidney by glomerular filtration and renal tubular secretion. In immunocompromised patients, acyclovir is effective for the prophylaxis and therapy of herpes simplex virus infections and for the treatment of herpes zoster and varicella. In nonimmunocompromised patients, acyclovir is beneficial in the therapy of herpes keratoconjunctivitis and in the therapy of genital herpes, with maximal benefit seen in those patients who have primary genital herpes. There is some benefit from acyclovir administration in patients with herpes zoster who are otherwise normal. The toxic reactions to acyclovir consist of phlebitis, local irritation, and occasionally, reversible renal dysfunction. Dose reduction is recommended in patients with impaired renal function.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6329117     DOI: 10.1001/archinte.144.6.1241

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  7 in total

Review 1.  Chemotherapy for herpes simplex virus infections.

Authors:  K S Erlich; J Mills
Journal:  West J Med       Date:  1985-11

2.  A randomized, double-blind, comparative trial comparing high- and standard-dose oral acyclovir for first-episode genital herpes infections.

Authors:  A Wald; J Benedetti; G Davis; M Remington; C Winter; L Corey
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

Review 3.  Adverse effects of drugs used in the management of opportunistic infections associated with HIV infection.

Authors:  B S Peters; E Carlin; R J Weston; S J Loveless; J Sweeney; J Weber; J Main
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

Review 4.  Selected nucleos(t)ide-based prescribed drugs and their multi-target activity.

Authors:  Gabriela Pastuch-Gawołek; Danuta Gillner; Ewelina Król; Krzysztof Walczak; Ilona Wandzik
Journal:  Eur J Pharmacol       Date:  2019-10-18       Impact factor: 4.432

Review 5.  Acyclovir for treating varicella in otherwise healthy children and adolescents: a systematic review of randomised controlled trials.

Authors:  Terry P Klassen; Elaine M Belseck; Natasha Wiebe; Lisa Hartling
Journal:  BMC Pediatr       Date:  2002-09-30       Impact factor: 2.125

6.  Therapeutic Strategy for the Prevention of Pseudorabies Virus Infection in C57BL/6 Mice by 3D8 scFv with Intrinsic Nuclease Activity.

Authors:  Gunsup Lee; SeungChan Cho; Phuong Mai Hoang; Dongjun Kim; Yongjun Lee; Eui-Joon Kil; Sung-June Byun; Taek-Kyun Lee; Dae-Hyun Kim; Sunghan Kim; Sukchan Lee
Journal:  Mol Cells       Date:  2015-08-07       Impact factor: 5.034

7.  A nucleic-acid hydrolyzing single chain antibody confers resistance to DNA virus infection in hela cells and C57BL/6 mice.

Authors:  Gunsup Lee; Jaelim Yu; Seungchan Cho; Sung-June Byun; Dae Hyun Kim; Taek-Kyun Lee; Myung-Hee Kwon; Sukchan Lee
Journal:  PLoS Pathog       Date:  2014-06-26       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.